Mark Plavsic
Chief Tech/Sci/R&D Officer bij AURA BIOSCIENCES, INC.
Vermogen: 2 M $ op 29-02-2024
Profiel
Dr. Mark Plavsic is Chief Technical Officer bij Fate Therapeutics, Inc. Dr. Plavsic was voordien werkzaam als Chief Technical Officer bij Lysogene SA en als Head- Process Development & Manufacturing bij Torque Therapeutics, Inc. Hij behaalde zijn doctoraatsdiploma aan de Universiteit van Belgrado en een doctoraatsdiploma aan de Universiteit van Belgrado.
Bekende belangen in openbare bedrijven
Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
---|---|---|---|---|
AURA BIOSCIENCES INC
0.26% | 15-03-2024 | 128 515 ( 0.26% ) | 1 M $ | 29-02-2024 |
FATE THERAPEUTICS, INC.
0.12% | 10-01-2023 | 123 705 ( 0.12% ) | 877 068 $ | 29-02-2024 |
Actieve functies van Mark Plavsic
Bedrijven | Functie | Begin |
---|---|---|
AURA BIOSCIENCES, INC. | Chief Tech/Sci/R&D Officer | 02-10-2023 |
TeraPore Technologies, Inc.
TeraPore Technologies, Inc. Chemicals: SpecialtyProcess Industries TeraPore Technologies, Inc. develops cutting-edge membrane technologies for high-permeability, high-resolution nanofiltration. The company was founded by Rachel Dorin in 2013 and is headquartered in | Director/Board Member | - |
Eerdere bekende functies van Mark Plavsic
Bedrijven | Functie | Einde |
---|---|---|
FATE THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 06-03-2023 |
Genzyme Corp.
Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Corporate Officer/Principal | - |
Torque Therapeutics, Inc.
Torque Therapeutics, Inc. BiotechnologyHealth Technology Torque Therapeutics, Inc. develops immunotherapies to address cancers focused on the specific modulation of immune cell subsets. The company was founded by Bart Henderson, Ulrik B. Nielsen, Darrell J. Irvine, and Thomas Lars Andresen and is headquartered in Cambridge, MA. | Corporate Officer/Principal | - |
LYSOGENE | Chief Tech/Sci/R&D Officer | - |
Opleiding van Mark Plavsic
University of Belgrade | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Beursgenoteerde bedrijven | 3 |
---|---|
AURA BIOSCIENCES, INC. | Health Technology |
FATE THERAPEUTICS, INC. | Health Technology |
LYSOGENE | Commercial Services |
Bedrijven in privébezit | 3 |
---|---|
Genzyme Corp.
Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Health Technology |
Torque Therapeutics, Inc.
Torque Therapeutics, Inc. BiotechnologyHealth Technology Torque Therapeutics, Inc. develops immunotherapies to address cancers focused on the specific modulation of immune cell subsets. The company was founded by Bart Henderson, Ulrik B. Nielsen, Darrell J. Irvine, and Thomas Lars Andresen and is headquartered in Cambridge, MA. | Health Technology |
TeraPore Technologies, Inc.
TeraPore Technologies, Inc. Chemicals: SpecialtyProcess Industries TeraPore Technologies, Inc. develops cutting-edge membrane technologies for high-permeability, high-resolution nanofiltration. The company was founded by Rachel Dorin in 2013 and is headquartered in | Process Industries |